Navigation Links
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Date:11/24/2008

el and selective adenosine2a receptor antagonist for Parkinson's disease (completing Phase II); results of a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease were reported showing that preladenant met the primary endpoint.

Presenters reviewed a range of other therapies in various stages of development in the company's six therapeutic areas: allergy/respiratory; cardiovascular/metabolic; central nervous system; immunology/infectious disease; oncology; and women's health.

Several earlier-stage research projects were also unveiled for the first time, including:

  • Two monoclonal antibodies for oncology -- robatumumab (anti-IGF-1R) in Phase II and anti-HGF in Phase I;
  • Two projects for Alzheimer's -- a beta secretase inhibitor and a gamma secretase inhibitor; and
  • A novel anti-inflammatory agent, anti-IL-23, in Phase I for chronic inflammatory conditions.

In Animal Health, the company highlighted its global leadership position and diverse portfolio and pipeline, with more than 120 small-molecule projects and 140 biological projects under way. The company also highlighted three growth corridors for Schering-Plough: companion animal; parasiticides; and geographic expansion in the U.S., Japan and emerging markets.

Webcast Information

A replay of the webcast of Schering-Plough's "R&D Update" meeting is available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. The replay will be available starting on Nov. 24 through 5 p.m. on Dec. 24.

Disclosure Notice

DISCLOSURE NOTICE:
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
3. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
4. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
5. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
6. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
7. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
11. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 This report analyzes the worldwide markets ... following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT systems), ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2013 through 2020. Also, ...
(Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
(Date:9/16/2014)... The Pulmonary Fibrosis Foundation (PFF) announced today ... 1,100 patients and families suffering from pulmonary fibrosis (PF) ... the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis ... to seek patient input in order to better understand ... "We applaud the FDA for focusing its attention on ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 263SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical applications, has entered into a new, ... SANTE (SES) of Algiers, Algeria for the distribution ...
... BME (BioMedical Enterprises, Inc.), a developer and manufacturer ... United States launch of Speed™. It is the first ... to orthopaedic and podiatric surgeons. BME, the ... its extensive knowledge in memory metal implant design to ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Algeria 2Misonix Announces New Distribution Agreement for Algeria 3
(Date:9/16/2014)... Keep that sexy decolletage as you age, and frame ... Face Whisperer Neck & Decollete Cream is made ... Sublime Beauty®. "It contains rich ingredients to care for the ... A special ingredient is Argireline, known as the natural botox, ... comes in an airless pump bottle, and is part of ...
(Date:9/16/2014)... Park City, UT (PRWEB) September 16, 2014 ... Health Benefits Solution, published new information on transitioning ... to Zane Benefits, with the Affordable Care Act ... sized businesses will be steering some or all ... comes as no surprise. With guaranteed issue plans, ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 UWDress.com, the ... new elegant evening wear assortment online. Additionally, ... products. All people can access big discounts now, up ... company’s elegant evening gowns are charming; it has won ... Along with evening outfits, it is also providing big ...
(Date:9/16/2014)... a healthcare climate where the costs of treatment ... study has found that radiation oncologists are using ... with early-stage breast cancer. The findings are scheduled ... of the American Society for Radiation Oncology in ... Radiotherapy for Elderly Women: Response to a Randomized ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous dress ... shoulder evening gown collection. According to the company’s sales ... rates (up to 69% off) at present. Additionally, all the ... “I am a frequent caller of your site. I like ... I feel quite happy. All items are of good quality. ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2
... 27 Aflac Incorporated,(NYSE: AFL ) announced today ... & Woods 2008 Insurance Conference. President and Chief Financial,Officer ... is,scheduled to make a presentation on September 3, 2008, ... Cloninger will discuss the,company,s outlook for the remainder of ...
... wages and benefits, HEMET, Calif., Aug. 27 The ... against the,board of directors of Valley Health System (VHS) for ... already voted to agree to., "I do this job ... said,Lisa Howell, a registered nurse at Menifee Valley Medical Center. ...
... HARRISBURG, Pa., Aug. 27 Believe it or not,women ... women,s oral,health needs change at different stages throughout their ... Association (PDA) offers a reminder that,understanding these evolving oral ... stage of life, is getting the oral health care ...
... help regain pre-pregnancy body, IRVINE, Calif., ... of post-baby body shaping solution VelaShape(TM),and other ... body,contouring, today reveals the results of the ... women,s desire to regain their,pre-pregnancy body. Syneron ...
... not all part of normal aging process , , WEDNESDAY, Aug. ... women who remain free of dementia will nonetheless undergo an ... years before their death, a new study reveals. , Verbal ... of this cognitive decline, which is not, the researchers stressed, ...
... women quit smoking during pregnancy to protect their unborn children from ... a few months of giving birth. , By shedding light ... that cigarette for good, a study by researchers at the University ... to help women quit and stay quit. , According to the ...
Cached Medicine News:Health News:Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2008 Insurance Conference 2Health News:State Board Issues Complaint: VHS Board Should Have Signed Contract With Caregivers 2Health News:What You Need to Know About Women's Oral Health 2Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 2Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 3Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 4Health News:Mental Skills Can Decline Years Before Dying 2Health News:Mental Skills Can Decline Years Before Dying 3Health News:Newly-defined factors may prevent postpartum smoking relapse 2Health News:Newly-defined factors may prevent postpartum smoking relapse 3
Used in the peritoneal cavity to remove large volumes of thick exudate....
100cc silicone evacuator...
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Medicine Products: